ABSTRACT Phosphoethanolamine (PEA) on Neisseria gonorrhoeae lipid A influences gonococcal inflammatory signaling and susceptibility to innate host defenses in in vitro models. Here, we evaluated the role of PEA-decorated gonococcal lipid A in competitive infections in female mice and in male volunteers. We inoculated mice and men with mixtures of wild-type N. gonorrhoeae and an isogenic mutant that lacks the PEA transferase, LptA. LptA production conferred a marked survival advantage for wild-type gonococci in the murine female genital tract and in the human male urethra. Our studies translate results from test tube to animal model and into the human host and demonstrate the utility of the mouse model for studies of virulence factors of the human-specific pathogen N. gonorrhoeae that interact with non-host-restricted elements of innate immunity. These results validate the use of gonococcal LptA as a potential target for development of novel immunoprophylactic strategies or antimicrobial treatments.
IMPORTANCE Gonorrhea is one of the most common bacterial sexually transmitted infections, and increasing antibiotic resistance threatens the use of currently available antimicrobial therapies. In this work, encompassing in vitro studies and in vivo studies of animal and human models of experimental genital tract infection, we document the importance of lipid A's structure, mediated by a single bacterial enzyme, LptA, in enhancing the fitness of Neisseria gonorrhoeae. The results of these studies suggest that novel agents targeting LptA may offer urgently needed prevention or treatment strategies for gonorrhea.
onorrhea remains a global health problem. The worldwide incidence of Neisseria gonorrhoeae infection equaled or surpassed that of Chlamydia trachomatis as the most common bacterial sexually transmitted infection for the first time in 2008 (1) . Increasing bacterial resistance to antibiotics used to treat gonorrhea, coupled with a dearth of new antimicrobial therapies in development, raises the specter of incurable N. gonorrhoeae infections (2) . The potential of adverse reproductive health consequences of untreatable gonococcal infections as well as increased HIV transmission in areas where both infections are prevalent is alarming (3) . Identification of new therapeutic and vaccine targets for gonorrhea may be more important now than ever before.
The most abundant lipid constituent of the N. gonorrhoeae outer membrane is lipooligosaccharide (LOS), a glycolipid comprised of an antigenically variable oligosaccharide core (4) attached to lipid A, which is frequently decorated by phosphoethanolamine (PEA) at the 4= position (5, 6) . The presence or absence of PEA-decorated lipid A (PEA-lipid A) profoundly influences inflammatory signaling (7, 8) and bacterial susceptibility to innate host defenses, including the bactericidal activities of normal human serum, complement, and cationic antimicrobial peptides (CAMPs) (5, 9) . To assess the importance of this structure during human infection, we constructed PEA transferase (lptA) deletion mutants of N. gonorrhoeae strain FA1090, which cannot add PEA to lipid A, and tested FA1090 ⌬lptA in competitive infections with isogenic lptA ϩ gonococci in the female murine lower genital tract and the human male urethra.
Strains. N. gonorrhoeae FA1090 is a porin serotype PIB-3, streptomycin (Sm)-resistant strain that has been used extensively in experimental human infection studies (10) . Bacteria were cultured on gonococcal agar (GC agar) supplemented with Kellogg's supplement I and ferric nitrate or in GC broth as described previously (11) with or without antibiotics as appropriate. Cultures were incubated at 35 to 37°C with 5 to 7% CO 2 .
FA1090 ⌬lptA was constructed without altering the antibiotic susceptibility of the wild-type strain, as previously described (12) . Briefly, a two-gene cassette containing both a selectable marker (chloramphenicol [Cm] acetyltransferase [CAT] conferring Cm resistance) and a counterselectable marker (rpsL, conferring Sm sensitivity on the naturally resistant strain FA1090) was cloned into the lptA gene and used to replace the wild-type gene in the FA1090 chromosome by allelic exchange; transformants were selected on GC agar with 1 g Cm/ml. The resulting intermediate strain was Cm resistant and Sm sensitive. A second transformation replaced the CAT rpsL cassette with an unmarked deletion encompassing approximately 80% of the lptA coding sequence; transformants were selected on GC agar with 100 g Sm/ml. The resulting strain, FA1090 ⌬lptA, was Cm sensitive and Sm resistant, as is wild-type strain FA1090. PCR amplification of the lptA locus and analysis of the FA1090 ⌬lptA genome sequence confirmed deletion of the gene in the mutant. The wild-type lptA gene from strain FA19 (identical to that of FA1090) was introduced into the FA1090 deletion mutant using the pGCC4 lptA ϩ vector as previously described (5) . The wild-type lptA gene is under the control of a lac promoter and is positioned between lctP and aspC in C=FA1090 ⌬lptA.
Electrophoretic characterization of gonococcal LOS and lipid A biochemical analyses. Whole-cell proteinase K-digested lysates of gonococci were resolved by Tricine-sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and LOS bands were identified by silver staining and Western blotting with monoclonal antibody 3F11 as previously described (9) . Lipooligosaccharides were purified from N. gonorrhoeae strains grown in GC broth, and lipid A was isolated by mild acid hydrolysis as previously described (9) . Lipid A was purified by extraction with chloroform and methanol; purified material was used for compositional analysis and determination of mass by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) using a model 4700 proteomics analyzer instrument (Applied Biosystems). Oligosaccharides were purified by size exclusion column chromatography; linkage analysis was performed by gas chromatography-mass spectrometry (GC-MS) using an Alltech AT-1 fused-silica capillary column on a HewlettPackard HP5890 gas chromatograph equipped with mass selective detector 5970 MSD.
PMB MIC determination. MICs of polymyxin B (PMB) were determined by spotting approximately 10 5 CFU of N. gonorrhoeae suspensions onto GC agar containing 2-fold differences in PMB, from 0.19 to 200 g PMB/ml; the MIC was defined as the highest concentration of PMB at which bacterial growth was observed after a 24-h incubation.
Experimental murine infection. All animal experiments were conducted at the Uniformed Services University of the Health Sciences according to the guidelines of the Association for the Assessment and Accreditation of Laboratory Animal Care under a protocol that was approved by the University's Institutional Animal Care and Use Committee. Female BALB/c mice (6 to 8 weeks old; National Cancer Institute) were treated with water-soluble 17␤-estradiol and antibiotics to increase susceptibility to N. gonorrhoeae as described previously (13) . Groups of mice were inoculated intravaginally with wild-type FA1090 combined with similar numbers of FA1090 ⌬lptA or C=FA1090 ⌬lptA CFU (total dose, 10 6 CFU N. gonorrhoeae; 7 mice/group). Vaginal swabs were collected every other day for 6 days starting on day 2 postinoculation and suspended in 100 l GC broth. Vaginal swab suspensions and inocula were cultured quantitatively on GC agar with 100 g Sm/ml (total number of CFU) and GC agar with Sm plus 10 g PMB/ml (FA1090 or C=FA1090 ⌬lptA CFU).
Experimental human infection. Procedures for participant recruitment, informed consent, intraurethral inoculation, and antibiotic treatment were as previously described (11) . Experimental human infections were conducted in the Clinical and Translational Research Center of the North Carolina Translational and Clinical Sciences Institute at the University of North Carolina at Chapel Hill according to the guidelines of the U.S. Department of Health and Human Services and the University's Institutional Review Board under a protocol that was approved as a U.S. investigational new device (IND). All study participants provided written informed consent. In two separate trials, volunteers received approximately equal numbers of N. gonorrhoeae FA1090 and FA1090 ⌬lptA CFU (total dose, 10 5 to 10 6 CFU N. gonorrhoeae; 3 men/trial). Gonococci in the inoculum suspensions were predominantly opacity-associated adhesin (Opa) negative and piliated and expressed the same PilE sequence as previously characterized FA1090 variants used in experimental human infection studies (14) . First-void urine specimens were obtained daily after inoculation. Urine sediment was cultured quantitatively on GC agar with 3 g vancomycin, 12.5 units nystatin, and 5 g trimethoprim lactate/ml, which permits the growth of FA1090 and FA1090 ⌬lptA. Up to 96 colonies per subject per culture were replica plated on GC agar with and without 7.5 g colistin/ml to distinguish the 2 strains; only wild-type FA1090 grows in the presence of the polycationic antibiotic colistin.
Competitive index calculations and statistics. For experimental murine and human infections, results were expressed as the competitive index (CI) for infected individuals using the equation CI ϭ [mutant CFU (output)/wild-type CFU (output)]/[mutant CFU (input)/wild-type CFU (input)]. For murine infections, in which total CFU and wild-type CFU were enumerated directly from vaginal specimen cultures, the limit of detection of 1 CFU was assigned for a strain that was not recovered from an infected mouse. For human infections, in which total CFU were enumerated directly from urine sediment cultures and up to 96 CFU per specimen was subcultured to identify wild-type or mutant colonies, the limit of detection (1/96 CFU) was assigned for the output proportion of a strain that was not detected from an infected man. A CI of Ͻ1 indicates that the mutant is less fit than the wild-type strain. For experimental human infections, we also compared the proportion of wild-type FA1090 among recovered N. gonorrhoeae isolates on the final day of participation for each infected subject to the proportion in the inoculum using a single-sample t test, with the proportion for the null hypothesis equal to 0.54 (the mean proportion of strain FA1090 in the inoculum). With a clearly directional hypothesis that the lptA ϩ strain would predominate, we used SigmaStat for Windows, v3.5 (Systat Software, Inc.), to calculate one-tailed statistics, with the type I error rate controlled at 0.05.
Lack of LptA-mediated PEA attachment to lipid A renders N. gonorrhoeae susceptible to a model CAMP in vitro. PEA addition at the 4= position of FA1090 lipid A was abrogated in FA1090 ⌬lptA and restored in the complemented strain C=FA1090 ⌬lptA (see Fig. S1A to D in the supplemental material). All strains produced 4.2-and 4.5-kDa LOS species; the former reacted with monoclonal antibody 3F11 (data not shown), confirming the presence of the lacto-N-neotetraose epitope associated with naturally acquired gonococcal urethritis (15) . As expected, deletion of lptA rendered FA1090 hypersusceptible to the model CAMP PMB (MICs, 100 g PMB/ml for FA1090 versus 0.78 g PMB/ml for FA1090 ⌬lptA), which was reversed by 32-fold in the complemented strain (data not shown). Importantly, in vitro growth rates of FA1090 ⌬lptA and wild-type FA1090 were indistinguishable (data not shown), and the ⌬lptA mutant did not show a fitness difference from wild-type FA1090 when cocultured in vitro through stationary phase in the absence of selective pressure (data not shown). From mixtures containing similar numbers of ⌬lptA mutant and wild-type FA1090 cells exposed to 5 g PMB/ml for 45 min in vitro, only wild-type N. gonorrhoeae with PEA-lipid A survived (data not shown), confirming the importance of this structure in CAMP resistance.
LptA-mediated PEA attachment to lipid A confers a survival advantage to N. gonorrhoeae during competitive infection in mice. Experimental infection of female BALB/c mice has been used to study innate host defenses against N. gonorrhoeae and the mechanisms by which gonococci evade these defenses (16) (17) (18) . Groups of female BALB/c mice were inoculated intravaginally with mixtures containing similar numbers of wild-type FA1090 and either FA1090 ⌬lptA or C=FA1090 ⌬lptA CFU (total dose, 5 ϫ 10 6 to 7 ϫ 10 6 CFU). The relative number of colonies of each strain recovered from vaginal swabs from infected mice was determined for up to 6 days after inoculation; output ratios of the two strains were normalized to the ratio of strains in the inoculum. We observed a 10-to 10,000-fold decrease in recovery of the lptA mutant relative to the wild-type parent strain FA1090 on days 2 to 6 of infection (Fig. 1A) . No mutant bacteria were recovered from several mice on multiple days postinoculation, whereas wild-type gonococci were recovered from these mice at levels of Ͼ10 3 to Ͼ10 6 CFU/ml vaginal swab suspension (Fig. 1A, open  circles) . Complementation of lptA restored recovery of the mutant by day 6 postinoculation (Fig. 1B) . Packiam et al. recently showed similar results with gonococcal strain FA19 during competitive infection in mice (19) .
LptA-mediated PEA attachment to lipid A confers a survival advantage to N. gonorrhoeae in the male urethra. To determine potential influences of host restriction differences in mice and humans (as well as differences in female and male genital tracts) on the contribution of PEA-lipid A to in vivo gonococcal survival, we performed competitive infections with wild-type N. gonorrhoeae FA1090 and the lptA mutant in the human challenge model of gonococcal urethritis (10) . Six subjects were inoculated intraurethrally with approximately equal mixtures of FA1090 and FA1090 ⌬lptA (total dose, 10 5 to 10 6 CFU). Five subjects (83%) developed gonococcal urethritis 2 to 4 days after inoculation; one remained uninfected for 5 days after inoculation ( Table 1 ). The relative number of each strain recovered was determined by subculturing up to 96 colonies from each positive urine sediment culture on selective media; output ratios of the two strains were normalized to the ratio of strains in the inoculum. Among colonies tested, only wild-type FA1090 was recovered (Table 1 ). We observed the maximum possible 100-fold decrease in the recovery of the lptA mutant relative to that of wild-type FA1090 on days 2 to 4 of infection (Fig. 1C) .
In our competitive infection studies, PEA-lipid A clearly provided a substantial fitness benefit to gonococci during infection, both in the human male urethra and in the murine female genital tract, compared to N. gonorrhoeae lacking PEA attached to lipid A. The mouse model likely underestimates the importance of PEAlipid A during infection due to differences in human and murine complement-binding proteins. However, some factors are apparently not host restricted (e.g., CAMP-mediated killing of the lptA mutant), confirming that the murine model can provide important information regarding the pathogenesis of gonococcal infection that is translatable to humans. In the mouse model, reduced infectivity resulting from lptA deletion in N. gonorrhoeae strain FA19 occurs only during competitive infections; noncompetitive infections with wild-type FA19, the FA19 ⌬lptA mutant, or the complemented FA19 lptA mutant produce similar kinetics of vaginal colonization and bacterial recovery (19) . However, only wildtype N. gonorrhoeae FA19 and the complemented FA19 lptA mutant induce proinflammatory host responses to gonococcal infection in female mice. John and colleagues previously demonstrated reduced inflammatory stimulation of human THP-1 cells by an lptA null mutant of the related pathogen N. meningitidis and by commensal Neisseria species that lack lptA (20) . Thus, PEA decoration of gonococcal lipid A not only increases inflammatory responses in vitro and during murine infection but also protects N. gonorrhoeae from the consequences of inflammation, including increased CAMP production. Experimental human infection 
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